Page last updated: 2024-08-16

temozolomide and veliparib

temozolomide has been researched along with veliparib in 47 studies

Research

Studies (47)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (17.02)29.6817
2010's32 (68.09)24.3611
2020's7 (14.89)2.80

Authors

AuthorsStudies
Bontcheva-Diaz, V; Bouska, JJ; Donawho, CK; Frost, DJ; Gandhi, VB; Giranda, VL; Gong, J; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Marsh, KC; Olson, AM; Osterling, DJ; Penning, TD; Shi, Y; Zhu, GD1
Bouska, JJ; Donawho, CK; Ellis, PA; Frost, DJ; Giranda, VL; Johnson, EF; Leverson, J; Liu, X; Luo, Y; Marcotte, PA; Olson, AM; Osterling, DJ; Penning, TD; Przytulinska, M; Rodriguez, LE; Shi, Y; Soni, N; Stavropoulos, J; Thomas, S; Tong, Y1
Artali, R; Barbarino, M; Battistuzzi, G; Carollo, V; Dallavalle, S; De Paolis, F; Gallo, G; Giannini, G; Guglielmi, MB; Milazzo, FM; Vesci, L1
Borghi, D; Busel, AA; Caprera, F; Casale, E; Ciomei, M; Cirla, A; Corti, E; D'Anello, M; Donati, D; Fasolini, M; Felder, ER; Forte, B; Galvani, A; Isacchi, A; Khvat, A; Krasavin, MY; Lupi, R; Montagnoli, A; Orsini, P; Papeo, G; Perego, R; Pesenti, E; Pezzetta, D; Posteri, H; Rainoldi, S; Riccardi-Sirtori, F; Scolaro, A; Sola, F; Zuccotto, F1
Cao, R; Chen, X; Ji, M; Xu, B; Zhou, J; Zhu, Z1
Feng, Y; Gao, Y; Gong, W; Guo, Y; Huo, CX; Jiang, B; Kuang, X; Liu, X; Liu, Y; Luo, L; Lv, L; Peng, H; Qi, R; Qin, Z; Qiu, M; Ren, B; Su, D; Sun, X; Tang, T; Wang, F; Wang, H; Wang, L; Wang, X; Wang, Z; Wei, M; Wu, Y; Xu, D; Xu, H; Yan, H; Yu, F; Zhao, Y; Zhou, C; Zhu, Y1
Colon-Lopez, M; Donawho, C; Ellis, PA; Frost, DJ; Giranda, VL; Kinders, R; LeBlond, D; Lin, CT; Liu, X; Luo, Y; Palma, J; Rodriguez, LE; Saltarelli, M; Shi, Y1
Colon-Lopez, M; Cox, BF; Donawho, C; Frost, D; Ghoreishi-Haack, N; Giranda, VL; Guan, R; Hradil, VP; Jarvis, K; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Palma, J; Penning, T; Rodriguez, LE; Rosenberg, SH; Shi, Y; Zhu, GD1
Carlson, BL; Clarke, MJ; Curtin, NJ; Decker, PA; Grogan, PT; Lou, Z; Mladek, AC; Mulligan, EA; Plummer, ER; Sarkaria, JN; Schroeder, MA; Wu, W1
Berg, SL; Bertuch, AA; Blaney, SM; Delaney, SL; Dolan, ME; Hegde, M; Horton, TM; Jenkins, G; Pati, D; Ribes-Zamora, A; Zhang, L1
Anderson, M; Giranda, VL; Han, EK; Johnson, EF; Lasko, L; Leverson, J; Liu, X; Luo, Y; McGonigal, T; Palma, J; Penning, T; Roberts, L; Rosenberg, S; Semizarov, D; Shi, Y; Shoemaker, AR; Wang, G; Zhu, GD1
Bukofzer, G; Donawho, CK; Ellis, PA; Frost, DJ; Giranda, VL; Lasko, L; Liu, X; Montgomery, D; Niquette, A; Palma, JP; Penning, TD; Rodriguez, LE; Rosenberg, SH; Shi, Y; Wang, YC; Zhu, GD1
Bachoo, RM; Burma, S; Camacho, CV; Hahm, B; McEllin, B; Mukherjee, B; Tomimatsu, N1
Donawho, CK; Ellis, PA; Harlan, JE; Iyer, R; Johnson, EF; Ladror, US; Liu, X; Maag, DX; Palma, JP; Patterson, MJ; Penning, TD; Ready, DB; Shi, Y; Shoemaker, AR; Solomon, LR; Soni, NB; Surber, BW; Xu, AJ1
Gu, F; Li, WL; Sun, ZF1
Barazzuol, L; Burnet, NG; Jena, R; Jeynes, JC; Kirkby, KJ; Kirkby, NF; Meira, LB1
Beijnen, JH; Beumer, JH; Buil, LC; Christner, SM; de Gooijer, MC; Lin, F; Roig, EM; van Tellingen, O; Würdinger, T1
Doroshow, JH; Ji, J; Morris, J; Murai, J; Pommier, Y; Takeda, S; Zhang, Y1
Alumkal, JJ; Carducci, MA; Cetnar, J; Chyla, B; Giranda, VL; Hussain, M; McKeegan, EM; Qian, J; Refici-Buhr, M; Shepherd, SP; Slovin, S1
Barrientos, A; Carazo, Á; Delgado, Á; López Viota, J; Muñoz-de-Rueda, P; Muñoz-Gámez, JA; Quiles-Perez, R; Ruiz-Extremera, Á; Salmerón, J; Sanjuán-Nuñez, L1
Bakken, KK; Boakye-Agyeman, F; Carlson, BL; Gupta, SK; Kizilbash, SH; Mladek, AC; Reid, J; Sarkaria, JN; Schroeder, MA1
Adesina, A; Blaney, SM; Boyett, J; Chen, A; Chyla, B; Fouladi, M; Giranda, V; Goldman, S; Kilburn, L; Kocak, M; Kun, L; Li, XN; McKeegan, E; Onar-Thomas, A; Pollack, IF; Su, JM; Thompson, P; Warren, KE1
Bahrami, A; Benavente, C; Bradley, C; Calabrese, C; Caufield, W; Dyer, MA; Freeman, BB; Gordon, B; Goshorn, R; Griffiths, LM; Hatfield, MJ; Karlström, Å; Loh, A; Miller, GM; Pappo, A; Potter, PM; Sablauer, A; Shelat, AA; Shirinifard, A; Snyder, SE; Stewart, E; Thiagarajan, S; Tsurkan, L; Twarog, NR; Wu, J1
Balvers, RK; Berghauser Pont, LM; Dirven, CM; Kleijn, A; Kloezeman, JJ; Lamfers, ML; Leenstra, S1
Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M1
Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H1
Cavaliere, R; Chakravarti, A; Chmura, SJ; Colman, H; de Groot, JF; Gilbert, MR; Grimm, SA; Kee, AY; Kesari, S; Krauze, A; Lieberman, FS; Mehta, M; Mohile, N; Robins, HI; Trotti, AM; Wang, F; Zhang, P1
Bakken, KK; Ballman, KV; Boakye-Agyeman, F; Carlson, BL; Cen, L; Decker, PA; Eckel-Passow, JE; Gupta, SK; Jenkins, RB; Kitange, GJ; Kizilbash, SH; Mladek, AC; Pokorny, JL; Reid, JM; Sarkar, G; Sarkaria, JN; Schroeder, MA; Sulman, EP; Verhaak, RG1
Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Lemasson, B; Li, Y; Rehemtulla, A; Ross, BD; Tsein, C; Wang, H; Zhu, Y1
de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA1
Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Giranda, VL; Han, HS; Isakoff, SJ; Johnson, EF; Kaufman, B; Maag, D; Puhalla, S; Qin, Q; Robson, M; Shepherd, SP; Telli, ML1
Giranda, V; Munasinghe, W; Nuthalapati, S; Xiong, H1
Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML1
Tutt, A1
Bensman, Y; Byers, LA; Cardnell, RJ; Chen, A; Chiappori, A; de Groot, P; Diao, L; Dowlati, A; Fleisher, M; Fujimoto, J; Hann, CL; Heymach, JV; Hurtado, B; Kris, MG; Krug, LM; Long, L; Owonikoko, TK; Pietanza, MC; Rudin, CM; Sulman, EP; Wang, J; Waqar, SN; Wistuba, II; Woo, KM1
Sidaway, P1
Bering, EA; Blough, MD; Bohm, AK; Bukhari, S; Cabral, M; Cahill, DP; Cairncross, JG; Chan, JA; Ezhilarasan, R; Gerber, A; Goodman, LD; Kaplan, DR; Kaufmann, AB; Lun, X; Marra, M; Mason, W; Maxwell, L; Pedersen, H; Ricks, CB; Robbins, SM; Safdar, S; Sayeed, W; Senger, DL; Shen, Y; Sulman, EP; Yuan, AL1
Beumer, JH; Chen, A; Gobburu, J; Gojo, I; Gopalakrishnan, M; Greer, JM; Karp, JE; Kiesel, BF; Mehrotra, S; Piekarz, R; Rudek, MA; Singh, R1
Liang, F1
Byers, LA; Diao, L; Pietanza, MC; Wang, J1
Adesina, A; Ansell, P; Baxter, PA; Billups, CA; Blaney, SM; Broniscer, A; Dunkel, IJ; Fouladi, M; Giranda, V; Kilburn, L; Li, XN; Onar-Thomas, A; Paulino, A; Poussaint, TY; Quaddoumi, I; Smith, ER; Su, JM; Thompson, P1
Baxter, P; Billups, C; Brown, D; Dunkel, IJ; Fangusaro, JR; Law, M; Onar-Thomas, A; Patay, Z; Poussaint, TY; Shiroishi, MS; Vajapeyam, S; Vezina, G1
Chen, AP; Das, B; Doroshow, JH; Foster, JC; Karlovich, C; Konaté, MM; Kummar, S; Leong, S; Li, MC; Lih, CJ; Meric-Bernstam, F; Moore, N; O'Sullivan Coyne, G; Palmisano, A; Piekarz, R; Polley, E; Raghav, KPS; Rosenberger, CL; Rubinstein, LV; Simon, R; Simpson, M; Sims, D; Waqar, S; Williams, PM; Zhao, Y1
Ashley, DM; Back, M; Barnes, EH; Buckland, ME; Fisher, L; Foote, MC; Hall, M; Khasraw, M; Koh, ES; Leonard, R; Lwin, Z; McDonald, KL; Rosenthal, M; Sim, HW; Simes, J; Sulman, EP; Wheeler, H; Yip, S1
Chabner, BA; Ellisen, LW; Garber, JE; Gelman, RS; Goss, PE; Habin, K; Isakoff, SJ; Keenan, TE; Overmoyer, B; Tung, NM; Winer, EP; Xu, J; Yeap, BY1
Al-Ansari, S; Bronckers, ALJJ; Brook, AH; de Lange, J; Jalali, R; Nadjmi, N; Raber-Durlacher, J; Rozema, FR; van Tellingen, O1

Trials

16 trial(s) available for temozolomide and veliparib

ArticleYear
Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
    Oncology (Williston Park, N.Y.), 2011, Nov-15, Volume: 25, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; Double-Blind Method; Humans; Melanoma; Neoplasm Staging; Temozolomide

2011
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; DNA Repair; Humans; Kallikreins; Male; Middle Aged; Pilot Projects; Poly(ADP-ribose) Polymerase Inhibitors; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Temozolomide; Treatment Outcome

2014
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
    Neuro-oncology, 2014, Volume: 16, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Young Adult

2014
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Dacarbazine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Survival Rate; Temozolomide; Young Adult

2015
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Salvage Therapy; Sorafenib; Temozolomide; Treatment Failure

2015
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
    Journal of neuro-oncology, 2016, Volume: 126, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult

2016
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
    Future oncology (London, England), 2017, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Clinical Protocols; Dacarbazine; Drug Monitoring; Female; Humans; Models, Statistical; Paclitaxel; Research Design; Sample Size; Temozolomide

2017
Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.
    Clinical pharmacokinetics, 2018, Volume: 57, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzimidazoles; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Temozolomide

2018
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 01-01, Volume: 29, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Breast Neoplasms, Male; Carboplatin; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Single-Blind Method; Temozolomide; Young Adult

2018
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 08-10, Volume: 36, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair Enzymes; Double-Blind Method; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Nuclear Proteins; Placebos; Poly (ADP-Ribose) Polymerase-1; Promoter Regions, Genetic; Small Cell Lung Carcinoma; Temozolomide; Tumor Suppressor Proteins

2018
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
    Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Maryland; Middle Aged; Models, Statistical; Mucositis; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Temozolomide; Tissue Distribution; Young Adult

2019
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
    Neuro-oncology, 2020, 06-09, Volume: 22, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Brain Stem Neoplasms; Child; Glioma; Humans; Temozolomide

2020
Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium.
    AJNR. American journal of neuroradiology, 2020, Volume: 41, Issue:4

    Topics: Adolescent; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Benzimidazoles; Brain Stem Neoplasms; Chemoradiotherapy; Child; Diffuse Intrinsic Pontine Glioma; Disease Progression; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Neuroimaging; Perfusion Imaging; Prognosis; Retrospective Studies; Survival Analysis; Temozolomide

2020
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
    JCO precision oncology, 2021, Volume: 5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carboplatin; DNA, Neoplasm; Double-Blind Method; Everolimus; Female; Gene Expression Profiling; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasms; Pyrazoles; Pyridones; Pyrimidinones; Temozolomide; Young Adult

2021
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
    Neuro-oncology, 2021, 10-01, Volume: 23, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Male; Middle Aged; Radiation Oncology; Temozolomide; Tumor Suppressor Proteins

2021
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
    Breast cancer research and treatment, 2021, Volume: 189, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; Breast Neoplasms; Carboplatin; Female; Germ-Line Mutation; Humans; Mutation; Temozolomide

2021

Other Studies

31 other study(ies) available for temozolomide and veliparib

ArticleYear
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
    Journal of medicinal chemistry, 2009, Jan-22, Volume: 52, Issue:2

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Biological Availability; Carboplatin; Cyclophosphamide; Dacarbazine; Dogs; Enzyme Inhibitors; Female; Haplorhini; Humans; Magnetic Resonance Spectroscopy; Melanoma, Experimental; Mice; Mice, SCID; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide

2009
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
    Journal of medicinal chemistry, 2009, Nov-12, Volume: 52, Issue:21

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzimidazoles; Biological Availability; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oxadiazoles; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Pyridines; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous

2009
Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.
    Bioorganic & medicinal chemistry letters, 2014, Jan-15, Volume: 24, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Mice; Mice, SCID; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolinones; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2014
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
    Journal of medicinal chemistry, 2015, Sep-10, Volume: 58, Issue:17

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Proliferation; Dacarbazine; Drug Screening Assays, Antitumor; Female; Heterografts; High-Throughput Screening Assays; Humans; Isoindoles; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Models, Molecular; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Rats, Sprague-Dawley; Structure-Activity Relationship; Temozolomide; Triple Negative Breast Neoplasms

2015
Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity.
    European journal of medicinal chemistry, 2017, May-26, Volume: 132

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line; Crystallography, X-Ray; Dacarbazine; Drug Design; Drug Synergism; Enzyme Inhibitors; Heterografts; Inhibitory Concentration 50; Poly (ADP-Ribose) Polymerase-1; Protein Binding; Structure-Activity Relationship; Temozolomide

2017
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
    Journal of medicinal chemistry, 2020, 12-24, Volume: 63, Issue:24

    Topics: Animals; Binding Sites; Carbazoles; Cell Proliferation; Dogs; Female; Fluorenes; Half-Life; Humans; Indoles; Isoenzymes; Mice; Microsomes; Molecular Docking Simulation; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2020
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Analytical biochemistry, 2008, Oct-15, Volume: 381, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biomarkers; Clinical Trials as Topic; Dacarbazine; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Melanoma, Experimental; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide

2008
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
    Molecular cancer research : MCR, 2008, Volume: 6, Issue:10

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Death; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; DNA Replication; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide

2008
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:2

    Topics: Animals; Benzimidazoles; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, Nude; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays

2009
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide

2009
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
    Molecular cancer research : MCR, 2009, Volume: 7, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Histones; Humans; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Rad51 Recombinase; Recombination, Genetic; RNA, Small Interfering; Sequence Homology; Temozolomide

2009
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Dec-01, Volume: 15, Issue:23

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Temozolomide; Tumor Suppressor Proteins

2009
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
    Cancer research, 2010, Jul-01, Volume: 70, Issue:13

    Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Benzimidazoles; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; DNA Damage; DNA Repair; Glioblastoma; Methylnitronitrosoguanidine; Mice; Mice, Transgenic; Poly(ADP-ribose) Polymerase Inhibitors; PTEN Phosphohydrolase; Recombination, Genetic; Temozolomide

2010
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; BRCA2 Protein; Cell Line, Tumor; Cysteine; Dacarbazine; DNA Repair; Drug Synergism; Female; Humans; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasms, Experimental; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays

2012
[Analysis of the relevant factors of mechanism for telozolomide chemoresistance].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzimidazoles; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Humans; Membrane Proteins; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Purines; Pyrimidines; Temozolomide; Tumor Suppressor Protein p53

2011
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
    Radiation oncology (London, England), 2013, Mar-19, Volume: 8

    Topics: Antineoplastic Agents; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Enzyme Inhibitors; Fluorescent Antibody Technique; Glioblastoma; Humans; Poly(ADP-ribose) Polymerases; Temozolomide

2013
ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Acridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Blood-Brain Barrier; Blotting, Western; Brain; Cell Line, Tumor; Dacarbazine; Dogs; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; LLC-PK1 Cells; Madin Darby Canine Kidney Cells; Metabolic Clearance Rate; Mice, Knockout; Mice, Nude; PTEN Phosphohydrolase; Swine; Temozolomide; Tetrahydroisoquinolines; Treatment Outcome

2014
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 349, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Chickens; Dacarbazine; DNA Damage; DNA Repair; Drug Synergism; Enzyme Inhibitors; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide

2014
Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Carcinoma, Hepatocellular; Chemistry, Pharmaceutical; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Carriers; Drug Combinations; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Liver Neoplasms; Magnetite Nanoparticles; Membrane Potential, Mitochondrial; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Signal Transduction; Technology, Pharmaceutical; Temozolomide

2015
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jul-15, Volume: 20, Issue:14

    Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Humans; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays

2014
Targeting the DNA repair pathway in Ewing sarcoma.
    Cell reports, 2014, Nov-06, Volume: 9, Issue:3

    Topics: Animals; Benzimidazoles; Camptothecin; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Enzyme Inhibitors; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays

2014
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
    Journal of translational medicine, 2015, Feb-26, Volume: 13

    Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Neoplastic Stem Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins

2015
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
    Journal of the National Cancer Institute, 2016, Volume: 108, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Polymerase Chain Reaction; Random Allocation; Temozolomide; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays

2016
Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.
    Neoplasia (New York, N.Y.), 2016, Volume: 18, Issue:2

    Topics: Animals; Apoptosis; Benzimidazoles; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Genetic Engineering; Glioblastoma; Humans; Magnetic Resonance Imaging; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide

2016
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Jan-15, Volume: 23, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genomics; Humans; Indoles; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Small Cell Lung Carcinoma; Temozolomide; Xenograft Model Antitumor Assays

2017
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 01-01, Volume: 29, Issue:1

    Topics: Benzimidazoles; Breast Neoplasms; Carboplatin; Humans; Neoplasm Recurrence, Local; Paclitaxel; Temozolomide

2018
SLFN11: a new synthetic lethal target?
    Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:9

    Topics: Benzimidazoles; Double-Blind Method; Humans; Lung Neoplasms; Nuclear Proteins; Small Cell Lung Carcinoma; Temozolomide

2018
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
    PloS one, 2018, Volume: 13, Issue:8

    Topics: Animals; Benzimidazoles; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioma; Humans; Mice; Neoplasm Grading; RNA, Small Interfering; Temozolomide; Xenograft Model Antitumor Assays

2018
Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet!
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 01-20, Volume: 37, Issue:3

    Topics: Adenosine Diphosphate; Benzimidazoles; Biomarkers; Double-Blind Method; Humans; Lung Neoplasms; Nuclear Proteins; Ribose; Temozolomide

2019
Reply to F. Liang.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 01-20, Volume: 37, Issue:3

    Topics: Benzimidazoles; Double-Blind Method; Humans; Lung Neoplasms; Temozolomide

2019
Tooth Formation as Experimental Model to Study Chemotherapy on Tissue Development: Effect of a Specific Dose of Temozolomide/Veliparib.
    Genes, 2022, 07-04, Volume: 13, Issue:7

    Topics: Animals; Benzimidazoles; Claudin-1; Mice; Models, Theoretical; Odontogenesis; Temozolomide

2022